340 related articles for article (PubMed ID: 12958153)
1. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
Wersinger C; Prou D; Vernier P; Sidhu A
FASEB J; 2003 Nov; 17(14):2151-3. PubMed ID: 12958153
[TBL] [Abstract][Full Text] [Related]
2. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter.
Wersinger C; Sidhu A
Biochemistry; 2005 Oct; 44(41):13612-24. PubMed ID: 16216085
[TBL] [Abstract][Full Text] [Related]
4. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Storch A; Hwang YI; Gearhart DA; Beach JW; Neafsey EJ; Collins MA; Schwarz J
J Neurochem; 2004 May; 89(3):685-94. PubMed ID: 15086525
[TBL] [Abstract][Full Text] [Related]
6. Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells.
Wersinger C; Banta M; Sidhu A
Neurosci Lett; 2004 Mar; 358(2):95-8. PubMed ID: 15026157
[TBL] [Abstract][Full Text] [Related]
7. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of dopamine transporter activity by alpha-synuclein.
Wersinger C; Sidhu A
Neurosci Lett; 2003 Apr; 340(3):189-92. PubMed ID: 12672538
[TBL] [Abstract][Full Text] [Related]
10. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter.
Pristupa ZB; McConkey F; Liu F; Man HY; Lee FJ; Wang YT; Niznik HB
Synapse; 1998 Sep; 30(1):79-87. PubMed ID: 9704884
[TBL] [Abstract][Full Text] [Related]
12. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death.
Kaul S; Anantharam V; Kanthasamy A; Kanthasamy AG
Brain Res Mol Brain Res; 2005 Sep; 139(1):137-52. PubMed ID: 15978696
[TBL] [Abstract][Full Text] [Related]
13. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide.
Adamczyk A; Kaźmierczak A; Strosznajder JB
Neurochem Int; 2006 Sep; 49(4):407-12. PubMed ID: 16546300
[TBL] [Abstract][Full Text] [Related]
15. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
[TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
[TBL] [Abstract][Full Text] [Related]
17. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice.
Pérez-Sánchez F; Milán M; Buendía P; Cano-Jaimez M; Ambrosio S; Rosenthal A; Fariñas I
Neuroscience; 2010 May; 167(2):261-76. PubMed ID: 20156526
[TBL] [Abstract][Full Text] [Related]
18. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?
Sidhu A; Wersinger C; Vernier P
FASEB J; 2004 Apr; 18(6):637-47. PubMed ID: 15054086
[TBL] [Abstract][Full Text] [Related]
19. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro.
Lehmensiek V; Tan EM; Schwarz J; Storch A
Neuroreport; 2002 Jul; 13(10):1279-83. PubMed ID: 12151787
[TBL] [Abstract][Full Text] [Related]
20. Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex.
Zhu J; Apparsundaram S; Bardo MT; Dwoskin LP
J Neurochem; 2005 Jun; 93(6):1434-43. PubMed ID: 15935059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
